Human Milk Oligosaccharides for Mitigating Acute Allergic Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergies are inadequate, particularly for children and infants, as they often come with side effects, do not address all types of allergies, and disrupt natural defenses, leading to increased susceptibility to immunological disorders.
Innovation Solution
Administering a nutritional composition containing human milk oligosaccharides (HMOs), specifically acidic or neutral HMOs without N-acetyl-lactosamine, to prevent or mitigate acute allergic responses by targeting mast cell-mediated immediate allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If pharmaceuticals such as antihistamines are used to treat allergies, then allergic symptoms are reduced, but side effects occur and natural defenses are disrupted
Solution Approach 1:
Human milk oligosaccharides (HMOs) serve as an intermediary substance that modulates the immune system's response to allergens without directly blocking histamine receptors. The HMOs interact with immune cells and microbiota to reduce allergic inflammation, providing symptom relief while avoiding the side effects associated with direct pharmaceutical intervention.
Solution Approach 2:
The patent converts the previously harmful effect of antibiotics disrupting microbiota into a beneficial approach by using HMOs to actively restore and support healthy microbiota communities. This transforms the problem of microbiota disruption into an opportunity to rebuild protective microbial ecosystems that naturally regulate immune responses.
2Object-affected harmful factors
If antibiotics are increased to treat infections, then infections are controlled, but natural microbiota-mediated immunological tolerance is disrupted
Solution Approach 1:
HMOs are administered to establish protective microbiota communities before allergic sensitization can occur or to restore tolerance after antibiotic disruption. This preliminary or restorative action prevents the development of immunological disorders by ensuring healthy microbiota are present to regulate immune responses.
Solution Approach 2:
The microbiota, supported by HMOs, performs self-regulation of immune responses without continuous external intervention. The restored microbial communities naturally maintain immunological tolerance through their metabolic activities and interactions with the immune system, reducing dependence on pharmaceutical interventions.
3Object-affected harmful factors
If avoidance of triggering foods is implemented for food allergies, then allergic reactions are prevented, but quality of life and nutritional intake are reduced
Solution Approach 1:
The patent changes the physiological parameters of the immune system and microbiota through HMOs, transforming the body's response to food allergens from hypersensitive to tolerant. This allows individuals to consume previously triggering foods without adverse reactions, eliminating the need for restrictive avoidance behaviors and improving quality of life.
Data Source
AI summary
A method for preventing or mitigating an acute allergic response in a subject is disclosed. The method includes a step of administering a nutritional composition to the subject. The nutritional composition includes at least one of an acidic or a neutral HMO, but does not include an N-acetyl-lactosamine.